Literature DB >> 33508133

Broad-spectrum rescue compounds for structural p53 mutations: perspective on 'Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site'.

Jia-Le Wu1, Shuo Chen1, Min Lu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33508133      PMCID： PMC8104952          DOI： 10.1093/jmcb/mjab007

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN： 1759-4685            Impact factor:   6.216


× No keyword cloud information.
  9 in total

Review 1.  Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.

Authors:  Hugues de Thé; Pier Paolo Pandolfi; Zhu Chen
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

2.  Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.

Authors:  Shuo Chen; Jia-Le Wu; Ying Liang; Yi-Gang Tang; Hua-Xin Song; Li-Li Wu; Yang-Fei Xing; Ni Yan; Yun-Tong Li; Zheng-Yuan Wang; Shu-Jun Xiao; Xin Lu; Sai-Juan Chen; Min Lu
Journal:  Cancer Cell       Date:  2020-12-24       Impact factor: 31.743

3.  Limits to Personalized Cancer Medicine.

Authors:  Ian F Tannock; John A Hickman
Journal:  N Engl J Med       Date:  2016-09-29       Impact factor: 91.245

Review 4.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

Review 5.  The tumor suppressor p53: from structures to drug discovery.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02-10       Impact factor: 10.005

6.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Authors:  Jude Canon; Karen Rex; Anne Y Saiki; Christopher Mohr; Keegan Cooke; Dhanashri Bagal; Kevin Gaida; Tyler Holt; Charles G Knutson; Neelima Koppada; Brian A Lanman; Jonathan Werner; Aaron S Rapaport; Tisha San Miguel; Roberto Ortiz; Tao Osgood; Ji-Rong Sun; Xiaochun Zhu; John D McCarter; Laurie P Volak; Brett E Houk; Marwan G Fakih; Bert H O'Neil; Timothy J Price; Gerald S Falchook; Jayesh Desai; James Kuo; Ramaswamy Govindan; David S Hong; Wenjun Ouyang; Haby Henary; Tara Arvedson; Victor J Cee; J Russell Lipford
Journal:  Nature       Date:  2019-10-30       Impact factor: 49.962

Review 7.  Targeting transcription factors in cancer - from undruggable to reality.

Authors:  John H Bushweller
Journal:  Nat Rev Cancer       Date:  2019-09-11       Impact factor: 60.716

8.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

Review 9.  The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Annu Rev Biochem       Date:  2016-05-04       Impact factor: 23.643
  9 in total
  1 in total

1.  Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells.

Authors:  Jiale Wu; Yuntong Li; Jiaqi Wu; Huaxin Song; Yigang Tang; Ni Yan; Lili Wu; Sujiang Zhang; ChunKang Chang; Min Lu
Journal:  Clin Transl Med       Date:  2021-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.